Workflow
康芝药业(300086) - 2017 Q3 - 季度财报
HONZHONZ(SZ:300086)2017-10-25 16:00

Financial Performance - Net profit attributable to shareholders was CNY 9,383,309.53, an increase of 6.61% year-on-year[7]. - Operating revenue for the reporting period was CNY 101,410,367.83, reflecting an increase of 8.41% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 2,794,870.92, up 86.90% year-on-year[7]. - Basic earnings per share were CNY 0.0209, representing a growth of 6.63% compared to the same period last year[7]. - The company reported a net profit of CNY 240,860,871.29, up from CNY 199,636,673.88[49]. - The net profit for the current period is CNY 9,159,458.79, an increase of 51.8% compared to CNY 6,057,566.63 in the previous period[59]. - The total profit for the current period is 53,547,061.31, compared to 41,853,011.88 in the previous period, indicating an increase of about 28.1%[68]. - The company's total comprehensive income for the current period is 40,062,250.51, compared to 26,493,792.95 in the previous period, marking an increase of approximately 51.3%[69]. Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 1,436,434.19, down 91.88% year-on-year[7]. - The company's operating cash flow decreased by 91.88% to ¥1,436,434.19, mainly due to reduced cash receipts from product sales[22]. - The total cash inflow from operating activities is 418,303,062.14, compared to 484,171,086.87 in the previous period, indicating a decrease of approximately 13.6%[76]. - Total cash outflow from operating activities was ¥250,243,854.27, compared to ¥116,775,891.42 in the prior period, resulting in a net cash flow from operating activities of -¥62,792,721.08[80]. - Cash flow from financing activities resulted in a net outflow of -¥42,119,416.67, compared to a net inflow of ¥16,718,944.41 in the previous period[82]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,154,333,222.28, a decrease of 1.60% compared to the end of the previous year[7]. - Total current assets decreased to ¥1,361,088,956.43 from ¥1,472,113,974.49, a decline of approximately 7.5%[44]. - Total liabilities decreased to CNY 241,634,141.98 from CNY 316,825,517.14[49]. - Owner's equity increased to CNY 1,912,699,080.30 from CNY 1,872,636,829.79[49]. - Cash and cash equivalents increased by 100.42% to ¥328,886,203.96, primarily due to the recovery of principal from financial products[20]. Investments - Long-term equity investments rose by 59.07% to ¥35,825,485.75, reflecting ongoing capital commitments to Beijing Hengzhuo Technology Holdings[20]. - The company reported a 364.45% increase in net cash flow from investing activities, totaling ¥205,473,118.37, due to the recovery of financial product principal[23]. - The company received ¥2,169,000,000.00 from investment recoveries, up from ¥1,944,500,000.00 in the previous period[80]. Shareholder Information - The company reported a total of 18,598 common shareholders at the end of the reporting period[12]. - The largest shareholder, Hainan Hongshi Investment Co., Ltd., held 39.49% of the shares, totaling 177,695,947 shares[12]. Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[38]. - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[39]. - The company has committed to avoiding competition with its subsidiaries and will not engage in any competing business[36]. - The company has adhered to its commitments without any breaches during the reporting period[38]. Operational Developments - Shenyang Kangzhi's production lines for decoction pieces and syrup have obtained the GMP certificate (Certificate No: LN20170017) during the reporting period[25]. - The company received a patent certificate from the Singapore Intellectual Property Office for a method and component for treating viral diseases during the reporting period[25]. - The company has plans for market expansion and product development, as indicated by its recent investments and certifications[33].